ICER releases obesity medicines white paper

US health technology assessor the Institute for Clinical and Economic Review (CER), in collaboration with researchers from Brown University, has published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.

The paper, entitled, “Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions,” seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.

Sarah Emond, president and chief executive of the ICER, said: “Obesity treatments have the potential to transform thousands of lives, but only if we ensure sustainable access for all patients. It is incumbent upon the entire health care system to focus on innovative pricing, coverage, payment, and delivery solutions, with the goal of broadening access to effective obesity medications. This paper outlines the policies and market reforms available to move beyond responding to the high costs with reduced access, while meaningfully addressing the concerns around budget impact.”